Skip to main content
CI

Clarix Imaging

Clarix Imaging offers the VSI-360™, an intraoperative volumetric specimen imaging system that provides true 3D reconstruction of lumpectomy specimens, enabling direct visualization of tissue margins without overlap. This technology enhances the accuracy of margin assessment in breast surgical oncology, achieving sensitivity up to 94% and specificity up to 85%, thereby reducing the need for additional surgeries.

Chicago, United StatesFounded 2016272K+ followers
Updated 20 months ago

Funding

$18.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

KF
Funding rounds are not available yet.

Founders

Product

Problem

Current methods for assessing lumpectomy specimens, such as two-dimensional specimen radiography and tomosynthesis, often result in overlapping tissue obscuring the margins. This can lead to inaccurate margin assessment and a higher likelihood of requiring additional surgeries for breast cancer patients.

Solution

Clarix Imaging's VSI-360™ is an intraoperative volumetric specimen imaging system that provides true 3D reconstruction of lumpectomy specimens. The system allows direct visualization of tissue margins without overlap, enabling more accurate margin assessment during breast surgical oncology procedures. By providing a full set of high-resolution tissue slices, the VSI-360™ enhances the correlation between interpretation of the main lumpectomy specimen margin status and surgical pathology. This leads to a reduction in the need for repeat surgeries, improving patient outcomes and reducing healthcare costs.

Target Audience

The primary target audience includes breast surgical oncologists and pathology departments within hospitals and cancer centers.

Features

  • True 3D image reconstruction of the entire lumpectomy specimen volume
  • High-resolution tissue slices with no overlapping tissue obscuring the margins
  • Intraoperative use for immediate margin assessment
  • Demonstrated sensitivity up to 94% and specificity up to 85% in clinical studies
This profile is AI-generated and may contain inaccuracies.